Lexicon Pharmaceuticals (LXRX) Restructuring Costs (2010 - 2017)

Lexicon Pharmaceuticals (LXRX) has 8 years of Restructuring Costs data on file, last reported at $2.1 million in Q1 2017.

• Restructuring Costs for Q1 2017 came in at $2.1 million, up 117.72% year-over-year; the trailing twelve-month figure through Dec 2017 was $2.1 million (up 398.86% YoY), and the FY2017 annual result was $2.1 million, up 398.86% from the prior year.
• Restructuring Costs rose to $2.1 million in Q1 2017 per LXRX's latest filing, from -$2.1 million in the prior quarter.
• Over five years, Restructuring Costs peaked at $3.4 million in Q3 2015 and troughed at -$5.3 million in Q4 2013.
• A 5-year average of $408937.5 and a median of $846000.0 in 2014 frame the typical range for Restructuring Costs.
• The sharpest annual moves came in 2013 and 2016: Restructuring Costs slumped 2544.5% in 2013, then jumped 4083.33% in 2016.
• A 5-year view of Restructuring Costs shows it stood at -$5.3 million in 2013, then soared by 117.21% to $910000.0 in 2014, then dropped by 14.07% to $782000.0 in 2015, then tumbled by 374.42% to -$2.1 million in 2016, then soared by 197.9% to $2.1 million in 2017.
• Business Quant data shows LXRX's Restructuring Costs at $2.1 million in Q1 2017, -$2.1 million in Q3 2016, and $478000.0 in Q2 2016.